4D Molecular Therapeutics, Inc. - Common Stock (FDMT)

Looking for insights into the US markets one hour before the close of the markets on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

4D Molecular's 4D-150 showed sustained vision and anatomical improvements with fewer injections in DME, supported by regulatory alignment.

As we await the opening of the US market on Friday, let's delve into the pre-market session and discover the top gainers and losers shaping the early market sentiment.

Discover the top movers in Thursday's after-hours session and stay informed about the post-market dynamics.

4D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

4D Molecular Therapeutics stock drops after the company shared interim data from the PRISM Phase 1/2 trial and details on its Phase 3 4FRONT study for wet AMD. The Phase 3 study comparing 4D-150 to Regeneron's Eylea is set to begin in Q1 2025.

FDMT stock results show that 4D Molecular Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

4D Molecular Therapeutics reports 24-week interim data from its PRISM Phase 2 trial, showing 77% of wet AMD patients injection-free with 4D-150. The trial highlights safety and efficacy in reducing anti-VEGF treatments.

Goldman Sachs initiates coverage on RGNX, citing potential of gene therapy platform.